JP Morgan Chase
CRL icon

JP Morgan Chase’s Charles River Laboratories CRL Stock Holding History

JP Morgan Chase’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,400
Closed -$6M – 7478
2023
Q4 		$6M Buy
+25,400
New +$5M ﹤0.01% 2925
2022
Q2 		– Sell
-109,400
Closed -$31.1M – 6519
2022
Q1 		$31.1M Buy
+109,400
New +$33.7M ﹤0.01% 1441
2013
Q4 		– Sell
-500,000
Closed -$23.1M – 4112
2013
Q3 		$23.1M Buy
+500,000
New +$22.9M 0.01% 1249

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

JP Morgan Chase's CRL Position: Q2 2026 in Review

JP Morgan Chase increased its Charles River Laboratories (CRL) stake by 8.3% in Q2 2026, buying an estimated $3.91M and bringing the position to 286,317 shares worth $65.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

JP Morgan Chase first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $114M in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • JP Morgan Chase held 286,317 shares of Charles River Laboratories worth $65.1M as of Q2 2026.
  • JP Morgan Chase bought 21,967 Charles River Laboratories shares in Q2 2026, an estimated $3.91M.
  • Charles River Laboratories made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1294 holding.
  • JP Morgan Chase first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Charles River Laboratories position peaked at $114M in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.